US pricing pressure negatively impacted sales of some Johnson & Johnson products in the first quarter, weighing on the pharmaceutical segment, the company said April 18. Pricing pressure was notable in more competitive therapy areas like cardiovascular and metabolic disease, where J&J markets the SGLT-2 inhibitor Invokana (canagliflozen) for diabetes and the blood thinner Xarelto (rivaroxaban).
Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales
Johnson & Johnson had to offer steeper discounts in certain therapeutic categories like cardiovascular and metabolic disease, impacting first quarter sales. So far, the impact of a new biosimilar in the US has had minimal impact on Remicade.
More from Drug Pricing
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."
• By
CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.